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Experimental models of colitis in mice have been used extensively for analyzing the mole-
cular events that occur during inflammatory bowel disease (IBD) development. However, it
is uncertain to what extent the experimental models reproduce features of human IBD.This
is largely due to the lack of precise methods for direct and comprehensive comparison of
mouse and human inflamed colon tissue at the molecular level. Here, we use global gene
expression patterns of two sets of pediatric IBD and two mouse models of colitis to obtain
a direct comparison of the genome signatures of mouse and human IBD. By comparing the
two sets of pediatric IBD microarray data, we found 83 genes were differentially expressed
in a similar manner between pediatric Crohn’s disease and ulcerative colitis. Up-regulation
of the chemokine (C–C motif) ligand 2 (CCL2) gene that maps to 17q12, a confirmed IBD
susceptibility loci, indicates that our comparison study can reveal known genetic asso-
ciations with IBD. In comparing pediatric IBD and experimental colitis microarray data,
we found common signatures amongst them including: (1) up-regulation of CXCL9 and
S100A8; (2) cytokine–cytokine receptor pathway dysregulation; and (3) over-represented
IRF1 and IRF2 transcription binding sites in the promoter region of up-regulated genes, and
HNF1A and Lhx3 binding sites were over-represented in the promoter region of the down-
regulated genes. In summary, this study provides a comprehensive view of transcriptome
changes between different pediatric IBD populations in comparison with different coli-
tis models. These findings reveal several new molecular targets for further study in the
regulation of colitis.
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INTRODUCTION
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two major
forms of inflammatory bowel disease (IBD). The incidence rate of
pediatric CD in the US is 43 per 100,000 and 28 per 100,000 for
pediatric UC (1). As recently reported, the incidence and preva-
lence of pediatric IBD is rising in both developed and developing
countries (2). Growth retardation poses a significant threat to
the quality of life of 15–40% of children and adolescents with
IBD (3). Although environmental factors, microbes in the gas-
troenterological tract, genetic susceptibility, and immune system
dysfunction have been implicated, the etiology of pediatric IBD
remains incompletely understood.
During the development of IBD, the colon tissue changes
its genome transcription in response to pathological conditions,
which is a result of dysregulated interaction between the immune
system and enteric bacteria. The common feature of UC and
CD inflamed tissue genome transcription provides new clues for
pediatric IBD treatment. Although the microarray assay has been
performed on pediatric IBD, there is no comprehensive genome
transcription analysis for pediatric UC or CD. Here, we performed
transcriptome analysis using two sets of pediatric IBD microarray
data (4, 5), T-cell transfer colitis model microarray data (6), and
dextran sodium sulfate (DSS)-induced colitis microarray data (7)
generated from our laboratory and deposited in the National
Center for Biotechnology Information Gene Expression Omnibus
(NCBI GEO) database. Network and promoter analysis was per-
formed to identify differentially expressed genes in the inflamed
colon tissue from pediatric IBD patients versus experimental ani-
mal models. Comparison between pediatric IBD and experimental
colitis microarray data revealed the similarly expressed genes and
over-represented transcription factor binding sites (TFBS) in the
promoter regions of the dysregulated genes.
MATERIALS AND METHODS
PEDIATRIC IBD MICROARRAY DATASETS
To get a comprehensive view of the pediatric IBD genome tran-
scription profile, two sets of pediatric IBD microarray data were
selected from NCBI. Those two sets of microarray data were
obtained by using Affymetrix GeneChip Human Genome HG-
U133 plus 2.0 arrays that provide the most comprehensive cover-
age of transcribed human genome and contain probes for approx-
imately 22,634 genes. The microarray data were generated from
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pediatric colon in healthy controls, colon only CD, and colon
only UC. The dataset GSE10616 contained data from 11 control
samples, 14 CD samples, and 10 UC samples (4); the dataset
GSE9686 contained data from 8 control samples, 11 CD samples,
and 5 UC samples (5). Colon RNA was isolated from biopsies
obtained from patients and healthy controls at diagnosis. The
pediatric Crohn’s Disease Activity Index (PCDAI) and Pediatric
Ulcerative Colitis Clinical Activity Index (PUCAI) were used to
assess the clinical severity of the IBD sample.
GENESIFTER ANALYSIS
Two sets of pediatric IBD microarray data were uploaded to
GeneSifter software1 and normalized for comparison by Robust
Multichip Average (RMA) method. The gene expression difference
threshold was set to 2 with no upper limit. Data were analyzed with
a Student’s t -test followed by a Benjamini and Hochberg post test
to limit false discovery rates, as we previously reported (7).
INGENUITY PATHWAY ANALYSIS
To see the relationship between differentially expressed genes, the
selected genes identified as dysregulated in pediatric CD and pedi-
atric UC microarray data were then imported to IPA2 for network
analysis. Genes that were related to each other in biological func-
tions and/or diseases were organized into networks according to
the Ingenuity Pathways Knowledge Base (IPKB). IPKB is a database
derived from the data mining of the expression of and functional
relationships between molecules; this information was extracted
from published papers found in NCBI PubMed, Medline, and
several other databases.
CIS-REGULATORY ELEMENTS ANALYSIS
To identify common properties of promoter regions of differen-
tially expressed genes, the Affymetrix gene ID of identified genes
in pediatric UC and CD were uploaded to the cREMaG system3
(8). The sequence upstream the transcription start site (TSS) is
5000 base pairs, and the downstream sequence of TSS is 1000
base pairs. Promoter sequences were scanned with TFBS matrices
obtained from the JASPAR database and the public release of the
TRANSFAC database using the TFBS BioPerl module (9, 10). The
top 10 of the most over-represented binding sites were selected for
comparison analysis.
COMPARISON BETWEEN PEDIATRIC IBD AND EXPERIMENTAL COLITIS
MICROARRAY DATA
By directly comparing differential gene expression between human
and mouse inflamed colon tissue, we assessed the similarity
between human and mouse colitis. The dysregulated gene in DSS-
colitis (GEO data base accession number GSE22307) and T-cell
transfer colitis model (accession number GSE27302) were divided
into eight classes according to the genes expression trends. In the
DSS-colitis model, there were 1609 genes that were significantly
altered during the colitis development, with 501 progressively
up-regulated genes and 173 progressively down-regulated genes
1http://www.genesifter.com
2http://www.ingenuity.com
3http://www.cremag.org
(7). In the T-cell transfer colitis model, there were 1775 gene
expressions that were significantly changed, with 341 progres-
sively up-regulated genes and 361 progressively down-regulated
genes (6). The two sets of microarray data were obtained by using
the same platform, Mouse Genome 430 2.0 Array (Affymetrix),
which provided the most comprehensive annotated coverage of
the mouse genome, composing of over 34,000 well-characterized
mouse genes. The genes whose expression progressively changed
were correlated with inflammation development and were selected
for promoter binding sites analysis. The over-presented promoter
binding sites were further compared with the over-presented
binding sites obtained from pediatric IBD array data.
RESULTS
GENESIFTER ANALYSIS PEDIATRIC IBD MICROARRAY DATA
Analysis of GSE 9686 pediatric CD microarray data showed that
242 genes were differentially expressed,173 genes had up-regulated
expression, while 69 genes had down-regulated expression. Analy-
sis of the GSE 10616 pediatric CD microarray data showed that
there were 298 genes differentially expressed (the expression of 209
genes were up-regulated and 89 genes were down-regulated). After
comparing two sets of pediatric CD microarray data, we found the
expression of 167 genes was similarly changed. Among those 167
genes, 117 genes were up-regulated (Table S1 in Supplementary
Material), and 50 gene expressions were down-regulated (Table S2
in Supplementary Material).
In GSE9686 pediatric UC microarray data, there were 3860
genes differentially expressed (1717 genes were up-regulated, and
2143 genes were down-regulated). While in GSE10616 pediatric
UC, there were 1826 genes differentially expressed (1122 genes
were up-regulated and 704 genes were down-regulated). After
comparing the two sets of pediatric UC data, we found that
1071 genes were similarly up-regulated (Table S3 in Supplemen-
tary Material), and 736 genes were down-regulated (Table S4 in
Supplementary Material).
After comparing the data in Tables S1 and S3 in Supplementary
Material, we found that there were 65 genes up-regulated in pedi-
atric CD and pediatric UC, as shown in Table 1 and Figure 1A.
By comparing Tables S2 and S4 in Supplementary Material, we
found that there were 18 genes down-regulated in pediatric CD
and pediatric UC, as shown in Table 2 and Figure 1B.
Of the up-regulated genes, seven were from the CXC chemokine
family: CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL9, and
CXCL11, which are the key components of the cytokine–cytokine
receptor interaction pathway. CXCL1 is expressed by epithelial
cells, macrophages, and neutrophils (11, 12) and has neutrophil
chemoattractant activity (13). CXCL2 is secreted by macrophages
and monocytes and is a chemoattractant for polymorphonuclear
cells, leukocytes, and hematopoietic stem cells (11, 14, 15). CXCL5
is expressed in eosinophils and stimulates the chemotaxis of neu-
trophils (16). CXCL6 is a chemoattractant for neutrophils (17).
CXCL9 is an interferon (IFN)-dependent CXC chemokine, which
plays a pro-inflammatory role and has been found to be expressed
at high levels in UC tissue (18). CXCL11 is a chemoattractant for
activated T cells (19).
Of the down-regulated genes, four were solute carrier genes:
SLC16A9, SLC17A4, SLC23A3, and SLC3A1. The functions of
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Table 1 | Similarly up-regulated genes in pediatric IBD.
Gene ID Gene identifier GSE9686 CD GSE10616 CD GSE9686UC GSE10616UC
ACSL4 NM_022977 2.52 2.38 5.46 4.19
ADM NM_001124 2.19 2.25 3.70 3.17
ALDH1A2 AB015228 2.22 2.93 11.29 8.36
APCDD1 N48299 2.3 2.28 3.45 2.94
C4BPA NM_000715 2.01 2.50 10.31 5.94
CCL2 S69738 2.37 2.40 3.16 2.73
CCRL1 NM_016557 2.04 2.13 5.18 3.13
CDH11 D21254 2.52 2.34 6.21 4.08
CFB NM_001710 2.25 2.27 3.44 3.19
CFI BC020718 2.04 2.10 6.36 3.38
CH25H NM_003956 2.01 2.02 3.66 2.99
CHI3L1 M80927 6.15 5.72 33.46 21.81
CLDN1 AF101051 2.17 2.54 8.57 4.59
COL1A2 NM_000089 2.02 2.51 5.01 4.08
COL4A1 NM_001845 2.03 2.09 4.27 3.65
COL6A3 NM_004369 2.07 2.35 4.24 3.97
CXCL1 NM_001511 5.60 4.66 18.35 13.43
CXCL11 AF002985 6.82 5.61 14.19 12.26
CXCL2 M57731 3.35 3.39 10.29 9.44
CXCL3 NM_002090 2.89 3.27 9.44 8.29
CXCL5 AK026546 6.04 6.49 44.64 22.12
CXCL6 NM_002993 4.84 5.97 30.42 18.36
CXCL9 NM_002416 4.70 3.23 4.13 3.95
CYP27B1 NM_000785 2.03 2.19 2.35 2.22
CYR61 NM_001554 3.11 2.98 3.69 3.94
DERL3 AI655697 2.25 2.11 5.50 3.96
DUOX2 NM_014080 11.06 9.73 29.14 25.35
DUOXA2 AI821606 2.24 3.79 14.00 13.6
EMR2 NM_013447 2.55 2.54 5.01 4.20
FCGR1A X14355 2.82 2.39 2.88 2.61
FCRL5 AF343662 2.47 2.53 6.18 4.60
FN1 X02761 2.08 2.07 2.15 2.32
HSD11B1 NM_005525 2.68 2.57 4.12 3.84
IGKV1D-13 AW408194 3.19 2.52 6.96 4.87
IGLV1-44 U96394 3.63 3.26 15.57 9.51
IVD AF043583 3.00 3.08 11.48 7.58
KDELR3 NM_006855 2.38 2.50 5.09 4.13
LCN2 NM_005564 3.11 3.27 7.12 6.18
LOXL2 NM_002318 2.23 2.31 4.77 3.78
LPL BF672975 2.19 2.73 6.44 4.22
MMP1 NM_002421 5.44 6.69 41.57 22.03
MMP10 NM_002425 3.71 4.86 44.39 34.11
MMP3 NM_002422 11.65 10.85 66.73 49.68
MS4A2 NM_000139 2.33 2.12 3.73 2.96
NEBL NM_006393 2.24 2.29 3.94 3.24
NIACR2 NM_006018 4.90 4.04 7.94 8.03
NID1 BF940043 2.39 2.44 5.00 3.61
NOS2 L24553 2.12 2.02 4.07 3.54
NTN3 AF103529 3.64 2.91 9.44 6.10
PCDH7 NM_002589 2.07 2.16 7.21 4.27
PCSK1 NM_000439 3.25 4.54 11.66 8.33
PHLDA1 AA576961 2.89 2.91 9.53 6.48
(Continued)
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Table 1 | Continued
Gene ID Gene identifier GSE9686 CD GSE10616 CD GSE9686UC GSE10616UC
PSAT1 BC004863 3.49 2.49 9.33 5.50
S100A8 NM_002964 6.09 5.66 21.7 17.55
SEC24D NM_014822 2.35 2.19 4.85 3.49
SGMS1 AI377497 2.07 2.17 5.15 3.56
SLC6A14 NM_007231 7.11 10.32 56.81 51.22
SOCS3 AI244908 2.36 2.55 4.49 4.88
SOD2 W46388 2.29 2.31 3.86 3.03
SPINK4 NM_014471 6.02 5.83 17.04 11.85
TFPI2 L27624 3.68 3.22 10.00 7.01
TIMP1 NM_003254 2.29 2.34 5.44 4.89
TMEM158 BF062629 2.46 3.06 8.01 5.83
TMEM45A NM_018004 2.40 2.67 9.10 5.01
TYRP1 NM_000550 2.34 2.79 6.58 5.63
The two set of pediatric microarray data are downloaded from NCBI Gene Expression Omnibus (NCBI GEO) database. Values are mean fold change normalized to
control.
FIGURE 1 | Venn diagram illustration of gene expression similarity
between pediatric CD and UC patient sample microarray data.
(A) One-hundred seventeen genes were up-regulated from pediatric CD
compared with 1071 up-regulated genes from pediatric UC patients, with
65 genes being common between the two groups. (B) Fifty genes were
down-regulated from pediatric CD compared from 736 down-regulated
gene from pediatric UC patients, with 18 genes being common between
the two groups.
those down-regulated genes related to the transport of amino acids
(20), monocarboxylate (21), glutamate (22), sodium-phosphate
(23), and ascorbic acid (24).
INGENUITY ANALYSIS OF PEDIATRIC IBD MICROARRAY DATA
Those genes differentially expressed in pediatric CD and UC were
uploaded to Ingenuity software for network analysis. Those differ-
entially expressed genes in pediatric CD inflamed colon tissue were
organized into eight networks. The molecules in each network and
their top functions are listed in Table S5 in Supplementary Mater-
ial. Those differentially expressed genes in pediatric UC inflamed
colon tissue were organized into 25 networks, and the molecules
in each network and their top functions are listed in Table S6 in
Supplementary Material.
Figure 2 shows the first network of pediatric CD inflamed colon
tissue differentially expressed genes with their cell-to-cell signaling
functions and their interactions, as they relate to gastrointestinal
and hepatic system disease. As shown in Figure 2, the transcription
of nine chemokine genes was up-regulated, and those genes indi-
rectly react with the NF-κB complex. Figure 3 shows the network
2 differentially expressed genes in pediatric CD inflamed colon
tissue, which is composed of 15 up-regulated genes with func-
tions related to connective tissue and genetic disorders. MMP-1
and MMP-3 are located in the center of pediatric CD network
2. ChI3l1 is also implicated in this network through its indirect
reaction with IGFBP5.
Figure 4 shows the first network of pediatric UC with func-
tions related to cellular movement and signaling. Pediatric UC
network 1 is mainly composed of eleven G-protein-coupled recep-
tors, which were all up-regulated. Transcription of eight members
of the collage family was up-regulated as shown in Figure 5, with
functions related to connective tissue. Interestingly, ChI3L1 was in
the center of the pediatric UC network 2 (Figure 5), and ChI3L1
indirectly interacts with COL16A2 and TNC.
PROMOTER ANALYSIS OF PEDIATRIC IBD MICROARRAY DATA
Using the CREMaG system, we indentified over-presented TFBS
in the differentially expressed genes. The over-presented TFBS
of differentially regulated genes in pediatric CD is shown in
Tables S7–S10 in Supplementary Material. TFBS over-presented
in pediatric UC differentially expressed genes are shown in Table
S11 in Supplementary Material (for up-regulated genes) and in
Table S12 in Supplementary Material (for down-regulated genes).
The fold-difference in TFBS frequency was computed by dividing
the observed TFBS number by the background number.
By comparison, we found that there were six promoter
sequences (RELA, NF-κB, IRF2, Evi1, and IRF1) that were over-
presented in genes that were up-regulated in pediatric IBD. There
were six TFBS (Lhx3, MEF2A, HNF1A, Nobox, NR2F1, and Foxa2)
that were over-presented in the genes that were down-regulated in
pediatric IBD-inflamed colon tissue.
In the pediatric CD microarray data analysis, the NF-κB bind-
ing sequence was over-presented in the inflammatory-related
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Table 2 | Similarly down-regulated genes in pediatric IBD.
Gene ID Gene identifier GSE9686 CD GSE10616 CD GSE9686UC GSE10616UC
ABCB1 AF016535 −2.13 −2.02 −4.98 −4.04
ABCG2 AF098951 −4.93 −3.09 −8.52 −9.93
APOBEC3B NM_004900 −2.09 −2.05 −2.78 −2.80
AQP8 NM_001169 −4.57 −3.85 −28.58 −36.55
KRT12 NM_000223 −2.53 −2.22 −4.34 −3.69
LOC389023 AI499651 −2.07 −2.81 −3.56 −3.60
LOC643008 BF478120 −2.02 −2.00 −4.50 −2.58
MEP1B NM_005925 −5.08 −3.82 −6.37 −8.09
PCDH21 AI825832 −2.15 −2.24 −6.15 −3.70
PHLPPL AB023148 −2.13 −2.01 −4.29 −3.99
PLA2G12B BF939574 −2.29 −2.36 −2.80 −3.73
PRAP1 AA502331 −2.93 −2.33 −3.99 −4.65
SGK2 AI631895 −2.6 −2.92 −4.76 −4.35
SLC16A9 BG401568 −4.05 −3.08 −6.67 −4.65
SLC17A4 NM_005495 −2.64 −2.58 −8.08 −6.66
SLC23A3 AI263078 −2.61 −2.27 −5.24 −3.98
SLC3A1 M95548 −3.11 −2.43 −3.25 −4.76
WSCD1 AB011095 −2.17 −2.05 −2.62 −2.73
The two set of pediatric microarray data are downloaded from NCBI Gene Expression Omnibus (NCBI GEO) database. Values are mean fold change normalized to
control.
FIGURE 2 | Network 1 of pediatric CD has biological functions associated with cell-to-cell signaling and interaction, gastrointestinal disease, hepatic
system disease. Red shading indicates up-regulation, whereas green shading shows down-regulation.
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FIGURE 3 | Network 2 of pediatric CD has biological functions associated with connective tissue disorders, genetic disorder, and cardiovascular
disease. Red shading indicates up-regulation, whereas green shading shows down-regulation.
genes, such as CCL2, CXCL10, CXCL2, CXCL3, CXCL6, CXCL9,
and in other up-regulated genes in the pediatric CD-inflamed
colon tissue. The network analysis of pediatric CD (Figure 2)
also showed that NF-κB regulates chemokine gene expression.
Not surprisingly, in the pediatric UC microarray data promoter
analysis, the NF-κB binding site was also shown to be over-
represented in the promoter region of the up-regulated genes, as
it is well known that NF-κB plays a pivotal role in the expres-
sion of inflammatory mediators. The promoter region of 89
up-regulated genes (ICAM-1, COL1A1, WNT5A, CXCL5, IL-1B,
CXCL2, IL-6, IL-11, and others) in pediatric UC has the NF-κB
binding site.
COMPARISON OF PEDIATRIC IBD AND EXPERIMENTAL COLITIS
MICROARRAY DATA
The dysregulated KEGG pathway of GSE9686 pediatric UC and
GSE10616 pediatric UC is shown in Tables S13 and S14 in Sup-
plementary Material. The over-represented TFBS of progressively
up-regulated or down-regulated genes in the T-cell transfer colitis
model and the DSS-colitis model are shown in Tables S15–S18 in
Supplementary Material.
Comparison of differentially expressed genes in pediatric IBD
and progressively up-regulated or down-regulated genes in exper-
imental colitis is shown in Table 3 and Figures 6 and 7. The
comparison of the over-presented promoters in the differentially
expressed genes is shown in Table 4. Among them, the cytokine–
cytokine receptor pathway was dysregulated in all the four sets
of microarray data. CXCL9 and S100A8 were up-regulated in all
the four sets of microarray data. The expression of S100A8 was
also found to be up-regulated in the trinitrobenzene sulfonic acid
(TNBS)-induced colitis rat model and T-cell-mediated colitis in
SCID mice (25, 26).
Promoter analysis provided the possible common regulatory
mechanism of the expression of the dysregulated genes. As shown
in Table 4, the IRF1 and IRF2 binding sites were over-represented
in the up-regulated genes in pediatric IBD and experimental col-
itis. The HNF1A and Lhx3 binding sites were over-presented in
the down-regulated genes in the four sets of microarray data.
HNF1A is a transcription factor that regulates the expression of
cytokine-driven C-reactive protein, which is a clinical marker of
inflammation (27). Lhx3 is a transcription factor that is required
for pituitary and motor neuron development (28).
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FIGURE 4 | Network 1 of pediatric UC has biological functions associated with cellular movement, cell signaling, and nucleic acid metabolism. Red
shading indicates up-regulation, whereas green shading shows down-regulation.
As shown in Table 3, cytokine–cytokine receptor interaction
pathway is dysregulated in pediatric UC, CD, T-cell transfer, and
DSS-colitis model. While chemokine signaling pathway is dys-
regulated in pediatric UC, CD, and T-cell transfer colitis model,
but not in DSS-colitis model. Additionally, NF-κB binding site
is over-presented in the promoter region of up-regulated genes
in pediatric CD, UC, and T-cell transfer colitis, but not in DSS-
colitis model (Table 4). Thus, the comparison of dysregulated
KEGG pathway (Table 3) and the over-represented TFBS (Table 4)
showed that the T-cell transfer colitis model was better than the
DSS-induced colitis model at simulating pediatric IBD; however,
the DSS-colitis model was more similar to pediatric UC than
pediatric CD, as the DSS model has more common dysregulated
pathways and molecules (Table 3) and over-represented TFBS in
the dysregulated genes with pediatric UC than CD (Table 4).
DISCUSSION
Our microarray analysis revealed that chitinase 3-like 1 (carti-
lage glycoprotein-39, CHI3L1) was up-regulated in pediatric IBD
samples. CHI3L1 has the ability to enhance the adhesion and inter-
nalization of bacteria in epithelial cells (29). In vivo, neutralizing
CHI3L1 with an antibody suppresses DSS-induced colitis, and this
neutralization dramatically decreases bacteria adhesion and inva-
sion of epithelial cells. It has been demonstrated that CHI3L1
expression is up-regulated in epithelial cells under inflammatory
conditions. CHI3L1 also activates Akt signaling in epithelial cells
through its chitin binding motif, and increases secretion of IL-
8 and TNF-α in a dose-dependent manner (30). Fecal CHI3L1
levels are positively correlated with pathology score (31). Serum
concentration of CHI3L1 is also elevated in IBD patients (32).
Thus, CHI3L1 might be selected as both a target and a marker of
pediatric IBD.
Cysteine-rich, angiogenic inducer 61 (CYR61 or CCN1) was
up-regulated in pediatric IBD. It has been demonstrated that
CCN1 up-regulates pro-inflammatory gene transcription, such
as TNF-α, IL-1α, IL-1β, IL-6, and IL-12b in mice macrophages
(33). This induction results from CCN1 direct activation of NF-
κB and increased TNF-α synthesis. CCN1 supports macrophage
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FIGURE 5 | Network 2 of pediatric UC has biological functions associated with connective tissue disorders, genetic disorder, and dermatological
diseases and conditions. Red shading indicates up-regulation, whereas green shading shows down-regulation.
adhesion through integrin αMβ2 and syndecan-4. Because mice
lacking CCN1 cannot develop in utero, involving vascular defects
in the placenta, CCN1 is also related with vasculogenesis during
embryogenesis (34). Moreover, CCN1 construct transfected mice
showed increased angiogenesis in colon tissue (35). Together, these
suggest that CCN1 might be a unique target to treat pediatric
IBD through inhibition of pro-inflammatory gene expression and
angiogenesis.
Chemokine (C–C motif) ligand 2 (CCL2), also known as
monocyte chemotactic protein-1 or small inducible cytokine
A2, was up-regulated in pediatric inflamed colon tissue. CCL2
attracts monocytes, memory T cells, and dendritic cells to sites
of tissue injury, infection, and inflammation (36, 37). Inter-
estingly, CCL2 is located in the confirmed CD and UC sus-
ceptibility loci 19q12 (38, 39). Increased expression of CCL2
(Table 1) in pediatric inflamed colon tissue supports the idea
that CCL2 might be one of the causal genes of pediatric IBD.
Interestingly, this has been demonstrated by nanomolar concen-
trations of CCL2 stimulating inflammatory responses of mono-
cytes and effector T cells, whereas picomolar CCL2 exerts a
global suppressive effect on T-cell trafficking into inflamed lymph
nodes (40), as confirmed by picomolar levels of CCL2 ame-
liorating TNBS- and DSS-induced colitis (41). Thus, before
targeting CCL2 for IBD therapy more information is needed
regarding its dose effect on human colon tissue inflammation
responses.
One major difference of genome transcription in adult IBD
versus pediatric IBD colon tissue is that there is fewer common
dysregulated genes found in adult IBD. Feng et al. found that 25
genes were up-regulated and 18 genes were down-regulated in
adult IBD inflamed colon tissue (42). We found that 65 genes
were up-regulated and 18 genes were down-regulated in pedi-
atric IBD colon tissue. Compared with those two studies, CXCL2
and CXCL3 were both up-regulated in pediatric and adult IBD,
and only ABCB1 was down-regulated in pediatric and adult IBD.
This comparison suggests that there is a large difference between
pediatric and adult IBD patients. Additionally, both studies show
that there is a difference between CD and UC genome transcrip-
tion patterns, which suggests that CD and UC have distinctive
pathogenesis.
Promoter analysis provided potential targets at the transcrip-
tion factor level. NF-κB transcription factors are comprised of
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Table 3 | Common dysregulated pathways and genes.
Dysregulated pathways Genes up-regulated Genes down-regulated
T-cell model
vs. pediatric
CD
Cytokine–cytokine receptor interaction,
chemokine signaling pathway, Leishmaniasis,
Chagas disease, asthma, malaria, NOD-like
receptor signaling pathway
CXCL1, CXCL10, CXCL2, CXCL5, CXCL9, DUOXA2, GBP1,
IL-1B, MMP3, PSAT1, S100A8, TGM2
ABCB1
T-cell model
vs. pediatric
UC
Cytokine–cytokine receptor interaction,
chemokine signaling pathway, cell adhesion
molecules (CAMs), hematopoietic cell lineage,
Leishmaniasis, malaria, Alzheimer’s disease,
Huntington’s disease, graft-vs.-host disease
ARL4C, CTSC, CD274, CDC6, CCR1, CXCL1, CXCL2,
CXCL9, CSF2RB, C1R, C2, DUOXA2, EGR2, PSAT1,
PYHIN1, RUNX2, S100A8, S100A9, SLPI, SRGN, STAT1,
SLAMF8, SLC7A11, SNX10, SOCS1, TGM2, WARS, UBD,
ZC3H12A
ABCB1, CHKA,
DENND1B, FGFR3,
HOXB5, HSD3B2,
RBM25, SCIN, VSIG2
DSS model
vs. pediatric
CD
Cytokine–cytokine receptor interaction, Toll-like
receptor signaling pathway, ECM-receptor
interaction
ACSL4, APCDD1, ALDH1A2, CCL2, CXCL10, CXCL9,
CHI3L1, HSD11B1, IGFBP5, LCN2, MMP10, MMP3, PCDH7,
S100A8, SOCS3
ANK3, AQP8, PHLPPL
DSS model
vs. pediatric
UC
Cytokine–cytokine receptor interaction,
complement and coagulation cascades, cell
adhesion molecules (CAMs), Toll-like receptor
signaling pathway, ECM-receptor interaction,
hematopoietic cell lineage
ACSL4, APCDD1, ALDH1A2, CTSK, CD300A, CD86, CCL2,
CCL3, CCR1, CXCL9, CHRDL2, COL18A1, CSF2RB,
CLEC7A, CRISPLD2, CYP1B1, EDNRA, EDNRB, EPHA3,
EMP3, GPR84, GJA1, IGFBP5, ICAM-1, IFIT3, IL-11, IL33,
IL-6, LMCD1, LCN2, LHFP, LUM, LCP2, MMP10, MMP12,
MMP2, MMP3, NR2F1, OLFML2B, OLFML3, OSMR,
PDE4B, PLXNC1, KCNJ8, PCOLCE, PSMB9, PCDH7,
PYHIN1, QK1, RSPO3, S100A8, S100A9, SAMSN1, SLPI,
SH3PXD2B, STAT1, SLAMF8, ST8SIA4, SOCS3, STX11,
TUBB6, TNFSF11, TNFRSF11B, TWIST1, VGLL3, WISP1
ABAT, ACVR1C, ANK3,
AQP8, ABCC6,
MALAT1, PHLPPL,
RBM25, SLC26A2,
SLC26A3, TRPM6
FIGURE 6 | Venn diagram illustration of gene expression similarity
between pediatric CD and experimental colitis model microarray data.
(A) One-hundred seventeen genes were up-regulated from pediatric CD
compared with 341 up-regulated genes from T-cell colitis model and 501
up-regulated genes from DSS-colitis model. (B) Fifty genes were
down-regulated from pediatric CD compared from 361 down-regulated
gene from T-cell colitis model and 173 down-regulated genes from
DSS-colitis model.
FIGURE 7 | Venn diagram illustration of gene expression similarity
between pediatric UC patient sample microarray data and
experimental colitis model microarray data. (A) One-thousand seventy
one genes were up-regulated from pediatric UC compared with 341
up-regulated genes from T-cell colitis model and 501 up-regulated genes
from DSS-colitis model. (B) Seven-hundred thirty six genes were
down-regulated from pediatric UC compared from 361 down-regulated
gene from T-cell colitis model and 173 down-regulated genes from
DSS-colitis model.
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Table 4 | Comparison promoter between animal model and pediatric
IBD.
Over-represented in
up-regulated genes
Over-represented in
down-regulated genes
T-cell model vs.
pediatric CD
IRF1 Lhx3
IRF2 MEF2A
NF-κB HNF1A
RELA Nobox
ELF5
T-cell model vs.
pediatric UC
IRF1 HNF1A
IRF2 Lhx3
NFYA Pax4
RELA MEF2A
FOXF2 IRF2
NF-κB Nobox
DSS model vs.
pediatric CD
IRF2 Lhx3
IRF1 HNF1A
Foxa2
DSS model vs.
pediatric UC
IRF2 HNF1A
Pax4 Lhx3
IRF1 Pax4
FOXF2 IRF2
Foxa2
five family members in mammalian cells: RelA (p65), RelB, c-Rel,
p50/p105 (NF-κB1), and p52/p100 (NF-κB2). Those members
form homo- or hetero-dimers of NF-κB complexes to regulate
the expression of a variety of genes (43). Interestingly, Stronati
et al. found that nuclear NF-κB and the binding activity of NF-
κB to a consensus DNA sequence were significantly increased
in the inflamed mucosa of patients, compared to controls (44).
In IBD patients, the increased NF-κB expression in mucosal
macrophages is accompanied with an increasing capacity of these
cells to produce and secrete TNF-α, IL-1, and IL-6 (45). Many
of the established immunosuppressive drugs for IBD, like cor-
ticosteroids, play anti-inflammatory roles, at least partly via the
inhibition of the NF-κB activity (46). The fact that the NF-κB
binding sites are over-represented in the T-cell transfer colitis
model, combined with the fact that the NF-κB binding sites are
over-represented in pediatric IBD inflamed colon tissue suggests
that NF-κB likely plays an important role in pediatric IBD. In
agreement with this idea, NF-κB has been extensively studied,
and different ways to block NF-κB have been evaluated for IBD
treatment. Unfortunately, due to significant side effects and liver
toxicity, optimal ways to block NF-κB to treat IBD has not been
realized (47).
Interferon regulatory factor-1 and -2 (IRF1 and IRF2) are
transcription factors that regulate expression of inflammatory-
related genes, but are primarily identified as transcription factors
which regulate the human IFN-α/β gene (48). Interestingly, our
promoter analysis showed that binding site of IRF1 and IFR2
are over-represented in the pediatric IBD up-regulated genes.
Additionally, Clavell et al. found increased expression of IRF1
in lamina propria mononuclear cells from patients with CD
(49). Compared with wild-type mice, production of TNF-α and
IFN-γ in IRF1−/− mice is greatly impaired (50). Mice with a
target mutation in IRF2 (IRF2−/−) exhibit significant inhibi-
tion of IL-12, IL-12R, IFN-γ, IL-1 β, and IL-6 expression (51).
It has been demonstrated that IRF2 recruits the NF-κB tran-
scription factor into the nucleus via physical interaction, which
enhances TNF-α-induced NF-κB transcription (52). Thus, IRF1
and IRF2 have the potential to be selective and potentially effec-
tive targets for the treatment of both experimental colitis and
pediatric IBD.
In conclusion, we performed pediatric IBD transcriptome
analysis and its cross-species comparison with experimental coli-
tis models. Identification of common dysregulated gene expres-
sion profiles, over-represented transcription binding sites, and
related transcription factors controlling dysregulated gene expres-
sion changes reveal several molecular targets that serve as novel
pathways for further study and potential therapy for pedi-
atric IBD.
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